Adalimumab
Title: Adalimumab
CAS Registry Number: 331731-18-1
CAS Name: Anti-(human tumor necrosis factor) immunoglobulin G1 (human monoclonal D2E7 heavy chain) disulfide with human monoclonal D2E7 light chain, dimer
Manufacturers' Codes: D2E7
Trademarks: Humira (Abbott)
Literature References: Fully human monoclonal antibody against tumor necrosis factor a (TNFa). Prepn: J. G. Salfeld et al., WO 9729131; eidem, US 6090382 (1997, 2000 both to BASF). Characterization: L. C. Santora et al., Anal. Biochem. 275, 98 (1999). Characterization of antigen binding: idem et al., ibid. 299, 119 (2001). Clinical trial in rheumatoid arthritis: A. A. den Broeder et al., Ann. Rheum. Dis. 61, 311 (2002); in combination with methotrexate: F. C. Breedveld et al., Arthritis Rheum. 54, 26 (2006); in psoriatic arthritis: P. J. Mease et al., ibid. 52, 3279 (2005). Review of pharmacology and clinical experience: K. P. Machold, J. S. Smolen, Expert Opin. Biol. Ther. 3, 351-360 (2003). Review of safety and efficacy in psoriasis and rheumatoid arthritis: T. Patel, K. B. Gordon, Dermatol. Ther. 17, 427-431 (2004); in psoriatic arthritis: P. J. Mease, Expert Opin. Biol. Ther. 5, 1491-1504 (2005).
Therap-Cat: Anti-inflammatory.
Keywords: Anti-inflammatory (Biological Response Modifier).

Others monographs:
Nux VomicaGold, ExplosiveBexaroteneSodium Phosphomolybdate
MexazolamFerric ThiocyanateDMAPVamicamide
Sulfuryl ChloridePyritinolAmodiaquinSaperconazole
3,5-DibromosalicylaldehydeFlucloronideTertiapinSepimostat
©2016 DrugLead US FDA&EMEA